

# Regenerative Medicine Market by Product (Stem Cell [Autologous, Allogenic], Immunotherapy, Gene Therapy, Tissue Engineering), Application (Musculoskeletal, Cancer, Dermatology, Wound care, Cardiovascular Diseases, Eye Disorders) - Global Forecast to 2028

<https://marketpublishers.com/r/R4DAC818B99EN.html>

Date: January 2024

Pages: 293

Price: US\$ 4,950.00 (Single User License)

ID: R4DAC818B99EN

## Abstracts

The global regenerative medicines market is projected to reach USD 49.0 Billion by 2028 from USD 16.0 Billion in 2023, at a CAGR of 25.1% during the forecast period of 2023 to 2028. Factors such as the wide scope in new therapeutic areas and collaborations and partnerships by major market players are predicted to uplift the market in the coming years. Additionally, rise in the focus of personalized medicine and rising regenerative medicine regulatory approvals will provide lucrative market growth. However, lack of long-term data and ethical and legal concerns and high cost of treatments are predicted to restrict the market.

“The cell therapy segment held the dominant share in the regenerative medicine market.”

Based on product, the global regenerative medicine market is segmented into gene therapy, cell therapy (stem cell therapy [cell transplantations, stem cell therapy products {autologous therapy, allogenic therapy}] cell-based immunotherapy products), and tissue engineering products. The increasing popularity of stem therapy is expected to drive the expansion of the cell therapy market.

“Musculoskeletal disorders segment accounted for the largest share of the therapeutic area segment in 2022.”

Based on therapeutic area, the regenerative medicine market is segmented into oncology, musculoskeletal disorders, neurology, ophthalmology, dermatology & wound care, cardiovascular diseases, and other applications. This can be attributed to the increasing prevalence of orthopedic disorders and growing interest on musculoskeletal regeneration research.

“APAC region is likely to grow at a faster pace.”

The regenerative medicine market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. APAC region is anticipated to grow at a significant CAGR during the forecast period. High burden of chronic diseases, growing per capita income, and the rising demand for new technologies are expected to support regenerative medicine market growth in the region.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 80%, and Demand Side - 20%

By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%

By Region: North America -55%, Europe -10%, Asia-Pacific -20%, Latin America -10%, MEA- 5%

List of Companies Profiled in the Report:

Novartis AG (Switzerland)

Biogen, Inc. (US)

Sarepta Therapeutics, Inc. (US)

Gilead Sciences, Inc. (US)

Amgen Inc. (US)

Smith+Nephew (UK)

MEDIPOST Co., Ltd. (Korea)

JCR Pharmaceuticals Co., Ltd. (Japan)

Takeda Pharmaceutical Company Limited (Japan)

CORESTEM, Inc (South Korea)

Vericel Corporation (US)

MIMEDX Group, Inc. (US)

Organogenesis Inc. (US)

Medtronic (Ireland)

Bristol-Myers Squibb Company (US)

Orthocell Ltd. (Australia)

Mesoblast Ltd. (Australia)

BioRestorative Therapies, Inc. (US)

Pluristem Therapeutics Inc. (US)

TEGOSCIENCE (South Korea)

ANTEROGEN.CO.,LTD. (South Korea)

Bluebird bio, Inc. (US)

Stempeutics Research Pvt Ltd. (India)

Sibiono GeneTech Co. Ltd. (China)

Aspect Biosystems Ltd. (Canada)

## Athersys, Inc. (US)

### Research Coverage:

This report provides a detailed picture of the regenerative medicine market. It aims to estimate the size and future growth potential of the market across different segments, such as product, therapeutic area and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

### Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall regenerative medicine market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

### The report provides insights on the following pointers:

Analysis of key drivers (Growing focus on personalized medicine, steep rise of regulatory approvals in regenerative medicine, rising collaborations and partnerships by major market players, increasing scope in new therapeutic areas), restraints (Lack of long-term data, Ethical and legal concerns and high cost of treatments), opportunities (Integration with artificial intelligence and big data, Harnessing the potential of 3D printing, Growing number of organ transplants) and challenges (Lack of favorable reimbursement policies across various regions) are influencing the growth of regenerative medicine market.

**Product Development/Innovation:** Detailed insights on newly launched products of the regenerative medicine market.

**Market Development:** Comprehensive information about lucrative markets – the report analyses the regenerative medicine market across varied regions.

**Market Diversification:** Exhaustive information about new products, untapped

geographies, recent developments, and investments in the regenerative medicine market.

**Competitive Assessment:** In-depth assessment of market shares, growth strategies, and product offerings of leading players include Novartis AG (Switzerland), Biogen, Inc. (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Amgen Inc. (US), Smith+Nephew (UK), MEDIPOST Co., Ltd. (Korea), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan) and CORESTEM, Inc (South Korea) and among others in the regenerative medicine market.

## Contents

### 1 INTRODUCTION

1.1 STUDY OBJECTIVES

1.2 MARKET DEFINITION

1.2.1 INCLUSIONS & EXCLUSIONS

1.3 MARKET SCOPE

1.3.1 MARKETS COVERED

1.3.2 YEARS CONSIDERED

1.3.3 CURRENCY CONSIDERED

1.4 RESEARCH LIMITATIONS

1.5 STAKEHOLDERS

1.6 SUMMARY OF CHANGES

1.7 IMPACT OF RECESSION ON REGENERATIVE MEDICINE MARKET

### 2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA

FIGURE 1 RESEARCH DESIGN

2.1.1 SECONDARY DATA

2.1.2 PRIMARY DATA

FIGURE 2 BREAKDOWN OF PRIMARIES: REGENERATIVE MEDICINE MARKET

2.2 MARKET SIZE ESTIMATION

FIGURE 3 MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS:  
REGENERATIVE MEDICINE MARKET, 2022

FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022

FIGURE 5 NOVARTIS AG: REVENUE SHARE ANALYSIS, 2022

FIGURE 6 PRODUCT-BASED REVENUE ANALYSIS, 2022

2.2.1 PRIMARY INSIGHTS

FIGURE 7 VALIDATION FROM PRIMARY EXPERTS

2.2.2 SEGMENT ASSESSMENT METHODOLOGY: REGENERATIVE MEDICINE  
MARKET

FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH

FIGURE 9 CAGR PROJECTIONS: REGENERATIVE MEDICINE MARKET

FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND  
OPPORTUNITIES IN REGENERATIVE MEDICINE MARKET

2.3 MARKET BREAKDOWN & DATA TRIANGULATION

FIGURE 11 DATA TRIANGULATION METHODOLOGY

## 2.4 STUDY ASSUMPTIONS

## 2.5 RISK ANALYSIS

## 2.6 IMPACT OF RECESSION ON REGENERATIVE MEDICINE MARKET

TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2024–2028 (% GROWTH)

TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)

TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)

## 3 EXECUTIVE SUMMARY

FIGURE 12 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)

FIGURE 13 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)

FIGURE 14 GEOGRAPHICAL SNAPSHOT OF REGENERATIVE MEDICINE MARKET

## 4 PREMIUM INSIGHTS

### 4.1 REGENERATIVE MEDICINE MARKET OVERVIEW

FIGURE 15 FOCUS ON PERSONALISED MEDICINE TO DRIVE MARKET GROWTH

### 4.2 NORTH AMERICA: REGENERATIVE MEDICINE MARKET

FIGURE 16 CELL THERAPY TO COMMAND LARGEST SHARE OF NORTH AMERICAN REGENERATIVE MEDICINE MARKET

### 4.3 REGENERATIVE MEDICINE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

## 5 MARKET OVERVIEW

### 5.1 INTRODUCTION

### 5.2 MARKET DYNAMICS

FIGURE 18 REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

#### 5.2.1 DRIVERS

5.2.1.1 Growing focus on personalized medicine

FIGURE 19 PERCENTAGE OF FDA APPROVALS FOR PERSONALIZED MEDICINE PRODUCTS (2018–2022)

5.2.1.2 Emerging applications in new therapeutic areas

TABLE 4 REGENERATIVE MEDICINE MARKET: EMERGING APPLICATIONS

5.2.1.3 Increasing collaborations and partnerships by major market players

5.2.1.4 Increasing regulatory approvals in regenerative medicine

TABLE 5 LIST OF KEY PRODUCT APPROVALS IN REGENERATIVE MEDICINE MARKET, 2021–2023

5.2.2 RESTRAINTS

5.2.2.1 Lack of long-term data

5.2.2.2 Ethical and legal concerns and high cost of treatments

5.2.3 OPPORTUNITIES

5.2.3.1 Harnessing the potential of 3D printing

5.2.3.2 Integration with artificial intelligence and big data

5.2.3.3 Growing number of organ transplants

5.2.4 CHALLENGES

5.2.4.1 Lack of favorable reimbursement policies across various regions

5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

FIGURE 20 REVENUE SHIFT TOWARD REGENERATIVE MEDICINE COMPANIES

5.4 PRICING ANALYSIS

5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT

TABLE 6 REGENERATIVE MEDICINE PRICE TREND

5.5 SUPPLY CHAIN ANALYSIS

FIGURE 21 SUPPLY CHAIN ANALYSIS: REGENERATIVE MEDICINE MARKET

5.6 VALUE CHAIN ANALYSIS

FIGURE 22 VALUE CHAIN ANALYSIS: REGENERATIVE MEDICINE MARKET

5.7 ECOSYSTEM ANALYSIS

FIGURE 23 REGENERATIVE MEDICINE MARKET: ECOSYSTEM ANALYSIS

TABLE 7 ROLE IN ECOSYSTEM

5.8 TECHNOLOGY ANALYSIS

FIGURE 24 KEY STEPS IN GENE THERAPY

TABLE 8 STEM CELL THERAPIES AND GENE THERAPIES

5.9 PATENT ANALYSIS

TABLE 9 REGENERATIVE MEDICINE MARKET: INDICATIVE LIST OF PATENTS

5.10 KEY CONFERENCES & EVENTS IN 2024–2025

5.10.1 REGENERATIVE MEDICINE CONFERENCES IN 2024–2025

TABLE 10 REGENERATIVE MEDICINE CONFERENCES IN 2024–2025

5.11 TARIFF & REGULATORY LANDSCAPE

5.11.1 FDA APPROVALS

5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS



TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

5.12 PORTER'S FIVE FORCES ANALYSIS

TABLE 15 REGENERATIVE MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS

5.12.1 THREAT OF NEW ENTRANTS

5.12.2 THREAT OF SUBSTITUTES

5.12.3 BARGAINING POWER OF BUYERS

5.12.4 BARGAINING POWER OF SUPPLIERS

5.12.5 DEGREE OF COMPETITION

5.13 KEY STAKEHOLDERS & BUYING CRITERIA

5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS

FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF REGENERATIVE MEDICINE PRODUCTS

5.13.2 BUYING CRITERIA FOR REGENERATIVE MEDICINE PRODUCTS

FIGURE 26 KEY BUYING CRITERIA FOR END USERS

5.14 PIPELINE ANALYSIS

TABLE 16 GENE THERAPY PRODUCTS UNDER CLINICAL TRIAL

TABLE 17 CELL THERAPY PRODUCTS UNDER CLINICAL TRIAL

## **6 REGENERATIVE MEDICINE MARKET, BY PRODUCT**

6.1 INTRODUCTION

TABLE 18 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

6.2 CELL THERAPY

TABLE 19 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 20 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY REGION, 2021–2028 (USD MILLION)

TABLE 21 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 22 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 23 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL

THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 24 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

#### 6.2.1 STEM CELL THERAPY

TABLE 25 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 26 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY REGION, 2021–2028 (USD MILLION)

TABLE 27 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 28 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 29 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 30 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

##### 6.2.1.1 Cell transplantations

###### 6.2.1.1.1 Potential of Allo-SCT in treating AML to drive segmental growth

TABLE 31 REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY REGION, 2021–2028 (USD MILLION)

TABLE 32 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 33 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 34 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 35 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

##### 6.2.1.2 Stem cell therapy products

TABLE 36 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 37 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY REGION, 2021–2028 (USD MILLION)

TABLE 38 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 39 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 40 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 41 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)

6.2.1.2.1 Autologous therapy

6.2.1.2.1.1 Low risk of post-treatment complications to support segment growth

TABLE 42 REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY REGION, 2021–2028 (USD MILLION)

TABLE 43 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 44 EUROPE: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 45 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 46 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

6.2.1.2.2 Allogeneic therapy

6.2.1.2.2.1 High potential in disease treatment to ensure demand and development

TABLE 47 REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY REGION, 2021–2028 (USD MILLION)

TABLE 48 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 49 EUROPE: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 50 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 51 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

6.2.2 CELL-BASED IMMUNOTHERAPY

6.2.2.1 Growing adoption of T-cell therapy in cancer treatment to support market growth

TABLE 52 REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY REGION, 2021–2028 (USD MILLION)

TABLE 53 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 54 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 55 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 56 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

## 6.3 GENE THERAPY

6.3.1 STRONG PRODUCT PIPELINE DUE TO BROADENING APPLICATIONS IN DISEASE TREATMENT TO DRIVE MARKET

TABLE 57 APPROVED GENE THERAPIES, 2022

TABLE 58 REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY REGION, 2021–2028 (USD MILLION)

TABLE 59 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 60 EUROPE: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 61 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 62 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

## 6.4 TISSUE ENGINEERING

6.4.1 HIGH DEMAND FOR TISSUE ENGINEERING PRODUCTS IN DERMATOLOGY & WOUND CARE APPLICATIONS TO DRIVE MARKET

TABLE 63 REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY REGION, 2021–2028 (USD MILLION)

TABLE 64 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 65 EUROPE: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 66 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 67 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)

## 7 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA

### 7.1 INTRODUCTION

TABLE 68 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE PRODUCTS, BY THERAPEUTIC AREA, 2021 VS. 2022

TABLE 69 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

### 7.2 ONCOLOGY

7.2.1 INCREASING STEM CELL TRANSPLANTS TO DRIVE MARKET

TABLE 70 INDICATIVE LIST OF COMMERCIALIZED REGENERATIVE CELL THERAPIES FOR ONCOLOGY APPLICATIONS

TABLE 71 REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)

TABLE 72 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 73 EUROPE: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 74 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 75 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

### 7.3 MUSCULOSKELETAL DISORDERS

7.3.1 RISING RESEARCH ON MUSCULOSKELETAL REGENERATION AND PREVALENCE OF ORTHOPEDIC DISORDERS TO DRIVE MARKET

TABLE 76 REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)

TABLE 77 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 78 EUROPE: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 79 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 80 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)

### 7.4 DERMATOLOGY & WOUND CARE

7.4.1 RISING USE OF WOUND CARE BIOLOGICS TO DRIVE MARKET

TABLE 81 INDICATIVE LIST OF REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR TREATMENT OF ACUTE & CHRONIC WOUNDS

TABLE 82 REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY REGION, 2021–2028 (USD MILLION)

TABLE 83 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 84 EUROPE: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 85 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 86 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION)

### 7.5 CARDIOVASCULAR DISEASES

7.5.1 INCREASING USE OF MSCS FOR CLINICAL RESEARCH ON IHD TO

## SUPPORT MARKET GROWTH

TABLE 87 REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION)

TABLE 88 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 89 EUROPE: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 90 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 91 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

## 7.6 OPHTHALMOLOGY

7.6.1 REGENERATION OF EYE TISSUES FOR AMD TO SUPPORT MARKET GROWTH

TABLE 92 LIST OF PIPELINE PRODUCTS FOR REGENERATIVE MEDICINE IN OPHTHALMOLOGY

TABLE 93 REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY REGION, 2021–2028 (USD MILLION)

TABLE 94 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 95 EUROPE: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 96 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 97 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

## 7.7 NEUROLOGY

7.7.1 GROWING NUMBER OF GENE THERAPY PRODUCTS APPROVED FOR NEUROLOGICAL DISEASE TREATMENT TO DRIVE MARKET GROWTH

TABLE 98 REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)

TABLE 99 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 100 EUROPE: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 101 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 102 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

## 7.8 OTHER THERAPEUTIC AREAS

TABLE 103 REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION)

TABLE 104 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 105 EUROPE: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 106 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 107 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)

## 8 REGENERATIVE MEDICINE MARKET, BY REGION

### 8.1 INTRODUCTION

FIGURE 27 NUMBER OF PLAYERS IN REGENERATIVE MEDICINE MARKET, BY REGION, 2020–2022

TABLE 108 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE (2022)

TABLE 109 REGENERATIVE MEDICINE MARKET, BY REGION, 2021–2028 (USD MILLION)

### 8.2 NORTH AMERICA

FIGURE 28 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT

TABLE 110 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 111 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 112 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 113 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 114 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 115 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

#### 8.2.1 US

8.2.1.1 Rising number of pipeline products for regenerative medicine to drive market

TABLE 116 US: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 117 US: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY

TYPE, 2021–2028 (USD MILLION)

TABLE 118 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 119 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 120 US: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

### 8.2.2 CANADA

8.2.2.1 Rising government initiatives for regenerative medicine research to drive market

TABLE 121 CANADA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 122 CANADA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 123 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 124 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 125 CANADA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

### 8.2.3 NORTH AMERICA: RECESSION IMPACT

## 8.3 EUROPE

TABLE 126 EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 127 EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 128 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 129 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 130 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 131 EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

### 8.3.1 GERMANY

8.3.1.1 Rising focus on clinical research and patent approvals to drive market

TABLE 132 GERMANY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 133 GERMANY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY,



BY TYPE, 2021–2028 (USD MILLION)

TABLE 134 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 135 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 136 GERMANY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

### 8.3.2 UK

8.3.2.1 Incorporating regenerative medicine into commercial healthcare services under NHS to drive market

TABLE 137 UK: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 138 UK: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 139 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 140 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 141 UK: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

### 8.3.3 FRANCE

8.3.3.1 Structured regulatory framework to drive regenerative medicine product pipeline

TABLE 142 FRANCE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 143 FRANCE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 144 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 145 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 146 FRANCE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

### 8.3.4 ITALY

8.3.4.1 Rising prevalence of neurological and cardiovascular disorders to drive market

TABLE 147 ITALY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 148 ITALY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY

TYPE, 2021–2028 (USD MILLION)

TABLE 149 ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 150 ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 151 ITALY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

#### 8.3.5 SPAIN

8.3.5.1 Favorable regulatory environment to drive product pipeline

TABLE 152 SPAIN: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 153 SPAIN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 154 SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 155 SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 156 SPAIN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

#### 8.3.6 REST OF EUROPE

TABLE 157 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 158 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 159 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 160 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 161 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

#### 8.3.7 EUROPE: RECESSION IMPACT

### 8.4 ASIA PACIFIC

FIGURE 29 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET SNAPSHOT

TABLE 162 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 163 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 164 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 165 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 166 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 167 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

#### 8.4.1 CHINA

8.4.1.1 Favorable government support for development of regenerative medicine to drive market

TABLE 168 CHINA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 169 CHINA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 170 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 171 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 172 CHINA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

#### 8.4.2 JAPAN

8.4.2.1 Regulatory amendments to pharmaceutical legislation to drive commercialization of therapies

TABLE 173 JAPAN: REGENERATIVE MEDICINE MARKET, BY PRODUCT,

### **2021–2028 (USD MILLION)**

TABLE 174 JAPAN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 175 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 176 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 177 JAPAN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,

### **2021–2028 (USD MILLION)**

#### 8.4.3 INDIA

8.4.3.1 Introduction of novel therapies for CVD and cancer to support market growth

TABLE 178 INDIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,

**2021–2028 (USD MILLION)**

TABLE 179 INDIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 180 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 181 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 182 INDIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

#### 8.4.4 SOUTH KOREA

8.4.4.1 Strong research base and availability of funds to support market growth

TABLE 183 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 184 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 185 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 186 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 187 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

#### 8.4.5 AUSTRALIA

8.4.5.1 Increasing incidence of sports injuries to support market growth

TABLE 188 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 189 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 190 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 191 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 192 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

#### 8.4.6 REST OF ASIA PACIFIC

TABLE 193 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 194 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 195 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 196 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 197 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

#### 8.4.7 ASIA PACIFIC: RECESSION IMPACT

### 8.5 LATIN AMERICA

TABLE 198 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 199 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 200 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 201 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 202 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 203 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

#### 8.5.1 BRAZIL

8.5.1.1 Gradual increase in pharmaceutical R&D to support market growth

TABLE 204 BRAZIL: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 205 BRAZIL: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 206 BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 207 BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 208 BRAZIL: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

#### 8.5.2 REST OF LATIN AMERICA

TABLE 209 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 210 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 211 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 212 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 213 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

8.5.3 LATIN AMERICA: RECESSION IMPACT

8.6 MIDDLE EAST

8.6.1 GROWING FOCUS ON GENETIC MEDICINE DEVELOPMENT PROJECTS TO DRIVE MARKET GROWTH IN COMING YEARS

TABLE 214 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY PRODUCT,

### **2021–2028 (USD MILLION)**

TABLE 215 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 216 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 217 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 218 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

8.6.2 MIDDLE EAST: RECESSION IMPACT

8.7 AFRICA

8.7.1 GROWING COLLABORATIONS TO SUPPORT GROWTH IN COMING YEARS

TABLE 219 AFRICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,

### **2021–2028 (USD MILLION)**

TABLE 220 AFRICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 221 AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)

TABLE 222 AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 223 AFRICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

8.7.2 AFRICA: RECESSION IMPACT

## 9 COMPETITIVE LANDSCAPE

### 9.1 INTRODUCTION

#### 9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS

TABLE 224 REGENERATIVE MEDICINE MARKET: STRATEGIES ADOPTED BY KEY PLAYERS

#### 9.3 REVENUE SHARE ANALYSIS

FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS (2020–2022)

#### 9.4 MARKET SHARE ANALYSIS

FIGURE 31 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)

TABLE 225 REGENERATIVE MEDICINE MARKET: DEGREE OF COMPETITION

#### 9.5 COMPANY EVALUATION MATRIX

##### 9.5.1 STARS

##### 9.5.2 EMERGING LEADERS

##### 9.5.3 PERVASIVE PLAYERS

##### 9.5.4 PARTICIPANTS

FIGURE 32 REGENERATIVE MEDICINE MARKET: COMPANY EVALUATION MATRIX, 2022

##### 9.5.5 COMPANY FOOTPRINT ANALYSIS

TABLE 226 REGENERATIVE MEDICINE MARKET: PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS

TABLE 227 REGENERATIVE MEDICINE MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS

#### 9.6 START-UP/SME EVALUATION MATRIX

##### 9.6.1 PROGRESSIVE COMPANIES

##### 9.6.2 RESPONSIVE COMPANIES

##### 9.6.3 DYNAMIC COMPANIES

##### 9.6.4 STARTING BLOCKS

FIGURE 33 REGENERATIVE MEDICINE MARKET: START-UP/SME EVALUATION MATRIX, 2022

##### 9.6.5 COMPETITIVE BENCHMARKING

TABLE 228 REGENERATIVE MEDICINE MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS

TABLE 229 REGENERATIVE MEDICINE MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS

#### 9.7 COMPETITIVE SCENARIO & TRENDS

##### 9.7.1 PRODUCT LAUNCHES

TABLE 230 REGENERATIVE MEDICINE MARKET: PRODUCT

APPROVALS/LAUNCHES, JANUARY 2020 TO DECEMBER 2023

#### 9.7.2 DEALS

TABLE 231 REGENERATIVE MEDICINE MARKET: DEALS, JANUARY 2020 TO DECEMBER 2023

#### 9.7.3 OTHER DEVELOPMENTS

TABLE 232 REGENERATIVE MEDICINE MARKET: OTHER DEVELOPMENTS, JANUARY 2020 TO DECEMBER 2023

## 10 COMPANY PROFILES

### 10.1 KEY MARKET PLAYERS

(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))\*

#### 10.1.1 NOVARTIS AG

TABLE 233 NOVARTIS AG: COMPANY OVERVIEW

FIGURE 34 NOVARTIS AG: COMPANY SNAPSHOT (2022)

#### 10.1.2 BIOGEN INC.

TABLE 234 BIOGEN INC.: COMPANY OVERVIEW

FIGURE 35 BIOGEN INC.: COMPANY SNAPSHOT (2022)

#### 10.1.3 GILEAD SCIENCES, INC.

TABLE 235 GILEAD SCIENCES, INC.: COMPANY OVERVIEW

FIGURE 36 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022)

#### 10.1.4 SAREPTA THERAPEUTICS, INC.

TABLE 236 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW

FIGURE 37 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2022)

#### 10.1.5 AMGEN, INC.

TABLE 237 AMGEN, INC.: COMPANY OVERVIEW

FIGURE 38 AMGEN, INC.: COMPANY SNAPSHOT (2022)

#### 10.1.6 SMITH+NEPHEW

TABLE 238 SMITH+NEPHEW: COMPANY OVERVIEW

FIGURE 39 SMITH+NEPHEW: COMPANY SNAPSHOT (2022)

#### 10.1.7 MEDIPOST CO., LTD.

TABLE 239 MEDIPOST CO., LTD.: COMPANY OVERVIEW

FIGURE 40 MEDIPOST CO., LTD.: COMPANY SNAPSHOT

#### 10.1.8 JCR PHARMACEUTICALS CO., LTD.

TABLE 240 JCR PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW

FIGURE 41 JCR PHARMACEUTICALS CO., LTD.: COMPANY SNAPSHOT (2022)

#### 10.1.9 TAKEDA PHARMACEUTICAL COMPANY LIMITED



TABLE 241 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW

FIGURE 42 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)

10.1.10 CORESTEM, INC.

TABLE 242 CORESTEM, INC.: COMPANY OVERVIEW

FIGURE 43 CORESTEM, INC.: COMPANY SNAPSHOT (2021)

10.1.11 VERICEL CORPORATION

TABLE 243 VERICEL CORPORATION: COMPANY OVERVIEW

FIGURE 44 VERICEL CORPORATION: COMPANY SNAPSHOT (2022)

10.1.12 MIMEDX GROUP, INC.

TABLE 244 MIMEDX GROUP, INC.: COMPANY OVERVIEW

FIGURE 45 MIMEDX GROUP, INC.: COMPANY SNAPSHOT (2022)

10.1.13 ORGANOGENESIS INC.

TABLE 245 ORGANOGENESIS INC.: COMPANY OVERVIEW

FIGURE 46 ORGANOGENESIS INC.: COMPANY SNAPSHOT (2022)

10.1.14 MEDTRONIC

TABLE 246 MEDTRONIC: COMPANY OVERVIEW

FIGURE 47 MEDTRONIC: COMPANY SNAPSHOT (2022)

10.1.15 BRISTOL-MYERS SQUIBB COMPANY

TABLE 247 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW

FIGURE 48 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2022)

10.2 OTHER PLAYERS

10.2.1 ORTHOCELL LTD.

TABLE 248 ORTHOCELL LTD.: COMPANY OVERVIEW

10.2.2 MESOBLAST LTD.

TABLE 249 MESOBLAST LTD.: COMPANY OVERVIEW

10.2.3 BIORESTORATIVE THERAPIES, INC.

TABLE 250 BIORESTORATIVE THERAPIES, INC.: COMPANY OVERVIEW

10.2.4 PLURISTEM THERAPEUTICS INC.

TABLE 251 PLURISTEM THERAPEUTICS INC.: COMPANY OVERVIEW

10.2.5 TEGOSCIENCE

TABLE 252 TEGOSCIENCE: COMPANY OVERVIEW

10.2.6 ANTEROGEN.CO.,LTD.

TABLE 253 ANTEROGEN.CO.,LTD.: COMPANY OVERVIEW

10.2.7 BLUEBIRD BIO, INC.

TABLE 254 BLUEBIRD BIO, INC.: COMPANY OVERVIEW

10.2.8 STEMPEUTICS RESEARCH PVT. LTD.

TABLE 255 STEMPEUTICS RESEARCH PVT. LTD.: COMPANY OVERVIEW

10.2.9 SIBIONO GENETECH CO. LTD.

TABLE 256 SIBIONO GENETECH CO. LTD.: COMPANY OVERVIEW

10.2.10 ASPECT BIOSYSTEMS

TABLE 257 ASPECT BIOSYSTEMS: COMPANY OVERVIEW

TABLE 258 ATHERSYS, INC.: COMPANY OVERVIEW

\*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

## **11 APPENDIX**

11.1 DISCUSSION GUIDE

11.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL

11.3 CUSTOMIZATION OPTIONS

11.4 RELATED REPORTS

11.5 AUTHOR DETAILS

## I would like to order

Product name: Regenerative Medicine Market by Product (Stem Cell [Autologous, Allogenic], Immunotherapy, Gene Therapy, Tissue Engineering), Application (Musculoskeletal, Cancer, Dermatology, Wound care, Cardiovascular Diseases, Eye Disorders) - Global Forecast to 2028

Product link: <https://marketpublishers.com/r/R4DAC818B99EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R4DAC818B99EN.html>